Use of microvesicles (MVS) for preparing a medicament having adjuvant activity on endothelial cell transplantation, particularlly in the treatment of diabetes by pancreatic islet transplantation, and related method

Vincenzo CANTALUPPI; CHIARA DEREGIBUS MARIA; CAMUSSI GIOVANNI

Use of microvesicles (MVS) for preparing a medicament having adjuvant activity on endothelial cell transplantation, particularlly in the treatment of diabetes by pancreatic islet transplantation, and related method

Vincenzo CANTALUPPI (Inventore), CHIARA DEREGIBUS MARIA (Inventore), CAMUSSI GIOVANNI (Inventore)

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Brevetto

Abstract

The invention relates to the use of microvesicles derived from cells of the endothelial cell lineage, preferably from endothelial progenitor cells, as an adjuvant agent in endothelial cell-pancreatic islet transplantation, particularly in the treatment of type I or type II diabetes by pancreatic islet transplantation. The adjuvant effect of the microvesicles consists in the improvement of survival and functionality of the transplanted islets. The adjuvant effect of the microvesicles is maintained even when the recipient is subjected to rapamycin-based immunosuppression.

Lingua originale	Inglese
Numero di brevetto	WO2009050742 (A1)
Stato di pubblicazione	Pubblicato - 1 gen 2007

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

http://hdl.handle.net/11579/71805

Altri file e collegamenti

handle

Fingerprint

Entra nei temi di ricerca di 'Use of microvesicles (MVS) for preparing a medicament having adjuvant activity on endothelial cell transplantation, particularlly in the treatment of diabetes by pancreatic islet transplantation, and related method'. Insieme formano una fingerprint unica.

Cita questo

@misc{97545782d7ea4ddbbfcc9db8a5fb3d49,

title = "Use of microvesicles (MVS) for preparing a medicament having adjuvant activity on endothelial cell transplantation, particularlly in the treatment of diabetes by pancreatic islet transplantation, and related method",

abstract = "The invention relates to the use of microvesicles derived from cells of the endothelial cell lineage, preferably from endothelial progenitor cells, as an adjuvant agent in endothelial cell-pancreatic islet transplantation, particularly in the treatment of type I or type II diabetes by pancreatic islet transplantation. The adjuvant effect of the microvesicles consists in the improvement of survival and functionality of the transplanted islets. The adjuvant effect of the microvesicles is maintained even when the recipient is subjected to rapamycin-based immunosuppression.",

author = "Vincenzo CANTALUPPI and MARIA, {CHIARA DEREGIBUS} and CAMUSSI GIOVANNI",

year = "2007",

month = jan,

day = "1",

language = "English",

type = "Patent",

note = "WO2009050742 (A1)",

}

Use of microvesicles (MVS) for preparing a medicament having adjuvant activity on endothelial cell transplantation, particularlly in the treatment of diabetes by pancreatic islet transplantation, and related method. / CANTALUPPI, Vincenzo (Inventore); MARIA, CHIARA DEREGIBUS (Inventore); GIOVANNI, CAMUSSI (Inventore).
Brevetto n.: WO2009050742 (A1). gen 01, 2007.

Risultato della ricerca: Brevetto

TY - PAT

T1 - Use of microvesicles (MVS) for preparing a medicament having adjuvant activity on endothelial cell transplantation, particularlly in the treatment of diabetes by pancreatic islet transplantation, and related method

AU - CANTALUPPI, Vincenzo

AU - MARIA, CHIARA DEREGIBUS

AU - GIOVANNI, CAMUSSI

PY - 2007/1/1

Y1 - 2007/1/1

N2 - The invention relates to the use of microvesicles derived from cells of the endothelial cell lineage, preferably from endothelial progenitor cells, as an adjuvant agent in endothelial cell-pancreatic islet transplantation, particularly in the treatment of type I or type II diabetes by pancreatic islet transplantation. The adjuvant effect of the microvesicles consists in the improvement of survival and functionality of the transplanted islets. The adjuvant effect of the microvesicles is maintained even when the recipient is subjected to rapamycin-based immunosuppression.

AB - The invention relates to the use of microvesicles derived from cells of the endothelial cell lineage, preferably from endothelial progenitor cells, as an adjuvant agent in endothelial cell-pancreatic islet transplantation, particularly in the treatment of type I or type II diabetes by pancreatic islet transplantation. The adjuvant effect of the microvesicles consists in the improvement of survival and functionality of the transplanted islets. The adjuvant effect of the microvesicles is maintained even when the recipient is subjected to rapamycin-based immunosuppression.

UR - https://iris.uniupo.it/handle/11579/71805

M3 - Patent

M1 - WO2009050742 (A1)

ER -